Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

This article is from an upcoming issue.

Certain features, such as pay-per-view, will only become available once the issue is published.

Metastatic Nasopharyngeal Carcinoma Treated With Intraarterial Combined With Intravenous Peptide Receptor Radionuclide Therapy

Zhu, Wenjia MD*,†; Zhang, Jingjing MD, PhD*; Singh, Aviral MD, MSc*; Kulkarni, Harshad R. MD*; Baum, Richard P. MD, PhD*

Clinical Nuclear Medicine: December 2019 - Volume 44 - Issue 12 - p 989–990
doi: 10.1097/RLU.0000000000002788
Interesting Images

Nasopharyngeal carcinoma may express somatostatin receptors (SSTR). We present a case with metastatic nasopharyngeal carcinoma in the liver, bone, and lymph nodes. The patient was in progression after chemotherapy, external beam radiation therapy (ERBT), atezolizumab, and cetuximab. Due to strong SSTR expression of the metastases, PRRT was applied. After 3 cycles of intravenous 177Lu-DOTATOC and 1 cycle of intraarterial 90Y-DOTATOC therapy, the hepatic and bone metastases showed excellent response after PRRT. No nephrotoxicity or myelotoxicity was observed.

From the *Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Germany

Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, CAMS and PUMC, Beijing, China.

Received for publication July 2, 2019; revision accepted July 20, 2019.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Richard P. Baum, MD, PhD, Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99437 Bad Berka, Germany. E-mail: richard.baum@zentralklinik.de.

Online date: October 29, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.